ArticleThoracic cancer2021
miR-493 by regulating of c-Jun targets Wnt5a/PD-L1-inducing esophageal cancer cell development.
Article in Thoracic cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- CD8 + T Cells in Gastrointestinal Cancer: a Perspective on Targeting MicroRNA.Journal of molecular medicine (Berlin, Germany) · 2025Review
- Disulfidptosis: A New Target for Parkinson's Disease and Cancer.Current issues in molecular biology · 2024Article
- Exploring Potential Biomarkers in Oesophageal Cancer: A Comprehensive Analysis.International journal of molecular sciences · 2024Review
- MicroRNAs: A novel signature in the metastasis of esophageal squamous cell carcinoma.World journal of gastroenterology · 2024Review
- Article
- Epigenetic modifications: Critical participants of the PD‑L1 regulatory mechanism in solid tumors (Review).International journal of oncology · 2022Review
- Roles of PTEN inactivation and PD-1/PD-L1 activation in esophageal squamous cell carcinoma.Molecular biology reports · 2022Review
- miR-664b-3p inhibits colon cell carcinoma via negatively regulating Budding uninhibited by benzimidazole 3.Bioengineered · 2022Article
- circFIG 4 drives the carcinogenesis and metastasis of esophagus cancer via the miR-493-5p/E2F3 axis.Thoracic cancer · 2022Article
- Epigenetic modifications in esophageal cancer: An evolving biomarker.Frontiers in genetics · 2022Review
- miR-493 by regulating of c-Jun targets Wnt5a/PD-L1-inducing esophageal cancer cell development.Thoracic cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEsophageal cancer is one of the most common cancers across the globe; the 5-year survival of esophageal cancer patients is still low. MicroRNA (miRNA) dysregulation has been implicated in cancer development, and the miRNAs play a pivotal role in esophageal cancer pathogenesis. It is urgently needed to find out how miRNA dysregulation was involved in esophageal cancer (EC) development.
methodsThrough experiments in vivo and in vitro, we explored potential signaling pathways, miR-493/Wnt5A/c-JUN loop, in EC. Their mechanistic roles in EC cell proliferation, migration, and invasion were investigated through multiple validation steps in EC9706 and TE13 cell lines and EC specimens.
resultsOverexpression of miR-493 attenuates esophageal cancer cell proliferation, migration, and invasion in vivo and in vitro. Moreover, miR-493 downregulation is an unfavorable factor in EC and negatively correlated with Wnt5A. The existence of miR-493 is also an important attribute of metabolism. Based on mechanism analyses, we show that miR-493 inhibits the activity of c-JUN and p-PI3K/p-AKT with enhanced p21 and directly regulates Wnt5A expression and function, whereas c-JUN binds the promoter region of miR-493 and suppressed the expression of miR-493, forming a negative feedback loop.
conclusionsThe miR-493/Wnt5A/c-JUN loop is a molecular feedback loop that refers to the development of esophageal cancer cells and a potential target for the treatment of esophageal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.